My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

17.39 -0.56 (-3.12%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗

July 13, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022 ↗

May 23, 2022

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Expert Ratings For Theravance Biopharma ↗

November 05, 2021

Within the last quarter, Theravance Biopharma (NASDAQ:TBPH) has observed t...

Via Benzinga

Theravance Biopharma's Earnings Outlook ↗

May 04, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's ↗

April 05, 2022

Theravance Biopharma Inc (NASDAQ: TBPH)

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Theravance Biopharma Stock Is Trading Lower After Hours ↗

April 04, 2022

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the...

Via Benzinga

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

Red Ink ↗

February 24, 2022

There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph

Via Talk Markets

Recap: Theravance Biopharma Q4 Earnings ↗

February 24, 2022

Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 23, 2022

Gainers SCYNEXIS (NASDAQ:SCYX) shares inc...

Via Benzinga

Give peace a chance ↗

February 15, 2022

Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.

Via Talk Markets

Earnings Scheduled For February 23, 2022 ↗

February 23, 2022

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...

Via Benzinga

Nuclear Winter ↗

February 11, 2022

Mexico is raising interest rates to 6%, from 5.5%.

Via Talk Markets

The Last Day In January ↗

January 31, 2022

The market is suspicious of the moves up to right matters.

Via Talk Markets

More Serious Matters ↗

January 14, 2022

Wall Street fell on new worries about inflation and a drop in retail sales levels.

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 12, 2022

Gainers Immuron (NASDAQ:IMRN) shares rose 36.6% to $3.58 during Wednesday's regular session. Trading volume for this security as of 12:32 EST is 35.0 million, which is...

Via Benzinga

50 Biggest Movers From Yesterday ↗

January 13, 2022

Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...

Via Benzinga

28 Stocks Moving In Wednesday's Mid-Day Session ↗

January 12, 2022

Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing...

Via Benzinga

48 Biggest Movers From Yesterday ↗

January 12, 2022

Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

January 03, 2022

Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) shares climbed 110.3% to $7.32. The FDA granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma's IMX-...

Via Benzinga

61 Biggest Movers From Yesterday ↗

January 04, 2022

Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa...

Via Benzinga

To sell or not to sell? ↗

December 14, 2021

Pfizer says its covid pill is 90% effective. PFE got higher target prices from Berenburg and Mizuho

Via Talk Markets

Wednesday Global Investing Report ↗

December 08, 2021

Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international...

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 08, 2021

Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares increased by 26.54% to $5.12 during Wednesday's regular session. Trading volume for Virpax Pharmaceuticals's...

Via Benzinga

Thursday Markets Overview ↗

December 02, 2021

Today we are seeing an across-the-board rise in stock prices on hopes for lower inflation and Omicron jabbing.

Via Talk Markets

Happy December ↗

December 01, 2021

Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices.

Via Talk Markets

Theravance Biopharma Pulls Plug On Izencitinib Crohn's Disease Trial ↗

November 16, 2021

Theravance Biopharma Inc (NASDAQ: TBPH) has voluntarily discontinued its Phase 2 study of izencitinib (gut-selective oral pan-JAK inhibitor) in Crohn’s...

Via Benzinga

Veteran's Day ↗

November 11, 2021

Stock markets took a tumble today across the board, but not as far down as at the opening.

Via Talk Markets

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.